title: [Current recommendations for the diagnosis and treatment of pulmonary hypertension].
abstract: Spiroergometry and Doppler stress echocardiography are recommended in cases of suspected but unproven pulmonary hypertension (PHT). Treatment of the underlying disease is indicated when there is pulmonary hypertension associated with disease of the left heart or the lungs. Surgery is indicated if there if the PHT is caused by chronic thromboembolism. PAH patients in NYHA class III-IV who do not meet response criteria to acute vasodilators, can be treated with prostanoids, endothelin receptor antagonists or phosphodiesterase 5 inhibitors.
authors.affiliation: Klinische Abteilung für Pulmologie, Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Auenbruggerplatz 20, A-8036 Graz. horst.olschewski@meduni-graz.at
authors.forename: H
authors.initials: H
authors.lastname: Olschewski
mesh_terms: D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors; D000465:Algorithms; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D015150:Echocardiography, Doppler / Q000379:methods; D025401:Echocardiography, Stress / Q000379:methods; D004691:Endarterectomy; D065128:Endothelin Receptor Antagonists; D016552:Ergometry / Q000379:methods; D006333:Heart Failure / Q000150:complications; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D008171:Lung Diseases / Q000150:complications; D011453:Prostaglandins / Q000627:therapeutic use; D011655:Pulmonary Embolism / Q000150:complications; D014665:Vasodilator Agents / Q000627:therapeutic use; D018487:Ventricular Dysfunction, Left / Q000150:complications; D018497:Ventricular Dysfunction, Right / Q000150:complications
chemical_list: D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D065128:Endothelin Receptor Antagonists; D011453:Prostaglandins; D014665:Vasodilator Agents; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human